Immune Checkpoint Inhibitors: all 7,817 studies that test it

Page 38 of 79. Open to participants first (2,632), then studies with results posted, then the rest; newest registration first within each.

• PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasTerminatedNCT03013491Phase 1/2Results posted
• Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedNCT03007732Phase 2Results posted
• Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on ChemotherapyCompletedNCT03007407Phase 2Results posted
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted
• Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results posted
• A Phase II Trial of Avelumab in Patients With Recurrent or Progressive OsteosarcomaCompletedNCT03006848Phase 2Results posted
• Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas CancerCompletedNCT03006302Phase 2Results posted
• SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCCompletedNCT03004183Phase 2Results posted
• Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Active, not recruitingNCT03003962Phase 3Results posted
• A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell LymphomaCompletedNCT03003520Phase 2Results posted
• Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017CompletedNCT03003468Phase 1/2Results posted
• An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03001882Phase 2Results posted
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results posted
• Safety and Efficacy of Avelumab in Small Intestinal AdenocarcinomaTerminatedNCT03000179Phase 2Results posted
• A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast CancerCompletedNCT02999477Phase 1Results posted
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02998528Phase 3Results posted
• Study of Pembrolizumab in Locally Advanced Esophageal AdenocarcinomaActive, not recruitingNCT02998268Phase 2Results posted
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT02996474Phase 1/2Results posted
• A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedNCT02996110Phase 2Results posted
• A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)TerminatedNCT02994953Phase 1Results posted
• PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaCompletedNCT02991482Phase 3Results posted
• A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Phase 2Results posted
• Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell CancerCompletedNCT02989714Phase 1/2Results posted
• HDCRT Plus Pembrolizumab in Advanced MalignanciesCompletedNCT02987166Phase 1Results posted
• A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)CompletedNCT02985957Phase 2Results posted
• A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerCompletedNCT02982954Phase 4Results posted
• Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-IntronTerminatedNCT02982720Phase 2Results posted
• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal CancerCompletedNCT02981524Phase 2Results posted
• Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast CancerCompletedNCT02981303Phase 2Results posted
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabTerminatedNCT02978443Phase 2Results posted
• Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)CompletedNCT02973997Phase 2Results posted
• Pembrolizumab in Refractory Advanced Esophageal CancerCompletedNCT02971956Phase 2Results posted
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerCompletedNCT02971761Phase 2Results posted
• Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to ChemotherapyActive, not recruitingNCT02971748Phase 2Results posted
• Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaCompletedNCT02970981Phase 2Results posted
• Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant GlioblastomaCompletedNCT02968940Phase 2Results posted
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedNCT02967692Phase 3Results posted
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted
• Pembrolizumab in Patients With Locally Advanced or Metastatic Skin CancerCompletedNCT02964559Phase 2Results posted
• Interleukin-2 and Pembrolizumab for Metastatic Kidney CancerCompletedNCT02964078Phase 2Results posted
• Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)CompletedNCT02964013Phase 1Results posted
• Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung CancerTerminatedNCT02963610Phase 1/2Results posted
• Pembrolizumab vs Topotecan in Patients With Small Cell Lung CancerTerminatedNCT02963090Phase 2Results posted
• A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.CompletedNCT02960854Phase 1Results posted
• Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaActive, not recruitingNCT02957968Phase 2Results posted
• Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung CancerCompletedNCT02955758Phase 2Results posted
• Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)CompletedNCT02955069Phase 2Results posted
• Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerCompletedNCT02954536Phase 2Results posted
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02953561Phase 1/2Results posted
• Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompletedNCT02953457Phase 2Results posted
• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)TerminatedNCT02952586Phase 3Results posted
• A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursCompletedNCT02952248Phase 1Results posted
• A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)CompletedNCT02951767Phase 2Results posted
• Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
• Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsTerminatedNCT02949843Phase 2Results posted
• Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryActive, not recruitingNCT02949219Phase 2Results posted
• A Study of Pembrolizumab in Patients With Neuroendocrine TumorsCompletedNCT02939651Phase 2Results posted
• Ipilimumab and Nivolumab in Leptomeningeal MetastasesCompletedNCT02939300Phase 2Results posted
• First in Human Study of IBI308 in Chinese Subjects With Advanced Solid TumorsCompletedNCT02937116Phase 1Results posted
• Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating AgentsCompletedNCT02936752Phase 1Results posted
• A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
• Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)TerminatedNCT02934503Phase 2Results posted
• PROSTVAC in Combination With Nivolumab in Men With Prostate CancerCompletedNCT02933255Phase 1/2Results posted
• A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary TractCompletedNCT02928406Phase 3Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedNCT02927769Phase 2Results posted
• A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)CompletedNCT02927301Phase 2Results posted
• Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based TherapyCompletedNCT02924883Phase 2Results posted
• Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaTerminatedNCT02923531Phase 1/2Results posted
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical CancerCompletedNCT02921269Phase 2Results posted
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedNCT02921256Phase 2Results posted
• Pembrolizumab in Metastatic Anal CancerCompletedNCT02919969Phase 2Results posted
• Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT02919683Phase 2Results posted
• Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With AtezolizumabTerminatedNCT02919449Phase 1Results posted
• Perioperative Chemo and Pembrolizumab in Gastric CancerCompletedNCT02918162Phase 2Results posted
• A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedNCT02913313Phase 1/2Results posted
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingNCT02912572Phase 2Results posted
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairActive, not recruitingNCT02912559Phase 3Results posted
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaCompletedNCT02908672Phase 3Results posted
• Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02907099Phase 2Results posted
• Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted
• A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCompletedNCT02905266Phase 3Results posted
• Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCompletedNCT02904954Phase 2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02901899Phase 2Results posted
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results posted
• Pembrolizumab in Ultramutated and Hypermutated Endometrial CancerCompletedNCT02899793Phase 2Results posted
• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCompletedNCT02899299Phase 3Results posted
• Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable MesotheliomaCompletedNCT02899195Phase 2Results posted
• Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney CancerCompletedNCT02899078Phase 1/2Results posted
• Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerCompletedNCT02898116Phase 1/2Results posted
• Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent GlioblastomaCompletedNCT02895360Phase 1/2Results posted
• Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerTerminatedNCT02892734Phase 2Results posted
• Pembrolizumab in HNSCC With Residual Disease After RadiationTerminatedNCT02892201Phase 2Results posted
• Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the BladderTerminatedNCT02891161Phase 1/2Results posted
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results posted
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerActive, not recruitingNCT02888743Phase 2Results posted
• Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02888665Phase 1/2Results posted
• Pembrolizumab In Central Nervous System MetastasesActive, not recruitingNCT02886585Phase 2Results posted

← Immune Checkpoint Inhibitors overview